Perampanel

AMPA-type glutamate receptor antagonist CAS# 380917-97-5

Perampanel

Catalog No. BCC1847----Order now to get a substantial discount!

Product Name & Size Price Stock
Perampanel: 5mg $311 In Stock
Perampanel: 10mg Please Inquire In Stock
Perampanel: 20mg Please Inquire Please Inquire
Perampanel: 50mg Please Inquire Please Inquire
Perampanel: 100mg Please Inquire Please Inquire
Perampanel: 200mg Please Inquire Please Inquire
Perampanel: 500mg Please Inquire Please Inquire
Perampanel: 1000mg Please Inquire Please Inquire
Related Products
  • Ampalex

    Catalog No.:BCC1359
    CAS No.:154235-83-3
  • Tezampanel

    Catalog No.:BCC1993
    CAS No.:154652-83-2
  • Noopept

    Catalog No.:BCC1804
    CAS No.:157115-85-0
  • LY450108

    Catalog No.:BCC1725
    CAS No.:376594-67-1
  • Aniracetam

    Catalog No.:BCC4219
    CAS No.:72432-10-1

Quality Control of Perampanel

Number of papers citing our products

Chemical structure

Perampanel

3D structure

Chemical Properties of Perampanel

Cas No. 380917-97-5 SDF Download SDF
PubChem ID 9924495 Appearance Powder
Formula C23H15N3O M.Wt 349.38
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO
Chemical Name 2-(2-oxo-1-phenyl-5-pyridin-2-ylpyridin-3-yl)benzonitrile
SMILES C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4
Standard InChIKey PRMWGUBFXWROHD-UHFFFAOYSA-N
Standard InChI InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Perampanel Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Perampanel Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Perampanel

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.8622 mL 14.3111 mL 28.6221 mL 57.2443 mL 71.5553 mL
5 mM 0.5724 mL 2.8622 mL 5.7244 mL 11.4489 mL 14.3111 mL
10 mM 0.2862 mL 1.4311 mL 2.8622 mL 5.7244 mL 7.1555 mL
50 mM 0.0572 mL 0.2862 mL 0.5724 mL 1.1449 mL 1.4311 mL
100 mM 0.0286 mL 0.1431 mL 0.2862 mL 0.5724 mL 0.7156 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Perampanel

Perampanel is a selective noncompetitive AMPA-type glutamate receptor antagonist which has demonstrated anticonvulsant activity in experimental seizure models and antiepileptic activity in clinical trials. Perampanel is currently in regulatory submission for partial-onset seizures associated with epilepsy.

Featured Products
New Products
 

References on Perampanel

Budget impact of perampanel as adjunctive treatment of uncontrolled partial-onset and primary generalized tonic-clonic seizures in the United States.[Pubmed:28236697]

Epilepsy Behav. 2017 Mar;68:196-202.

PURPOSE: To evaluate the budget impact (BI) of adopting Perampanel for adjunctive treatment of partial-onset seizures (POS), with or without secondarily generalized seizures, and the adjunctive treatment of primary generalized tonic-clonic seizures (PGTCS) in patients 12years or older in the United States. METHODS: A BI model was developed to estimate the potential BI of adopting adjunctive Perampanel from a US payer (direct costs only) and societal (direct and indirect costs) perspective over a 5-year period. Efficacy data for Perampanel and antiepileptic drug (AED) maintenance therapy were obtained from Perampanel phase III clinical trials. Drug, direct medical (healthcare provider, emergency room, and hospitalizations), and indirect (productivity loss) costs were obtained from appropriate sources (e.g., AnalySource(R) Online [wholesale acquisition costs], 2013 Optum Insight Clinformatics Database [market share percentages, direct medical costs per unit], and 2011-2013 National Health and Wellness Survey [NHWS; healthcare resource utilization, overall work impairment, and baseline distribution of patients across the 4 health states]). Mapping of seizure frequency to medical resource utilization and work impairment was obtained from Kantar Health's NHWS. RESULTS: In a hypothetical health plan of 1 million members, 660 (0.066%) members >/=12years old had uncontrolled POS (395 [59.8%]) or PGTCS (265 [40.2%]). During the first 5years of adoption of Perampanel, absolute BI (including drug, direct medical, and indirect costs) was $852, $2124, $3855, $5318, and $6397, respectively, for a cumulative absolute BI of $18,545. Drug cost was estimated to increase by $13,888, $34,646, $62,863, $86,728, and $104,326, respectively; however, this cost would be mostly offset by decreases in direct medical ($5041, $12,576, $22,818, $31,481, and $37,869, respectively) and indirect ($7995, $19,946, $36,190, $49,929, and $60,060, respectively) costs. Total per-member-per-month cost (drug and direct medical costs) was estimated to increase by $0.0007, $0.0018, $0.0033, $0.0046, and $0.0055 from years 1 to 5. CONCLUSIONS: Based on results of this BI model, increased cost of adopting Perampanel in a health plan of 1 million members would be minimal for payers, and societal costs would be close to neutral.

Perampanel in 12 patients with Unverricht-Lundborg disease.[Pubmed:28166365]

Epilepsia. 2017 Apr;58(4):543-547.

OBJECTIVE: Perampanel (PER) was used in 12 patients with Unverricht-Lundborg disease (ULD) to evaluate its efficacy against myoclonus and seizures. METHODS: We treated 11 patients with EPM1 mutations (6 F, 5 M, aged 13-62 years) and a 43-year-old man with de novo KCNC1 mutation. PER was introduced by 2 mg steps at 2-4 week intervals until 6 mg/day, with a possible dose reduction or dose increase. RESULTS: Ten patients had a clear clinical response of myoclonus, and five were able to reduce concomitant therapy. Improvement was noted sometimes as soon as with 2 mg/day. Epileptic seizures stopped on PER in the six patients who still had experienced generalized tonic-clonic or myoclonic seizures (100%). Some abatement of efficacy on myoclonus was seen in two patients who still retained some benefit. Weight gain was reported in six patients (50%). Psychological and behavioral side-effects were observed in six patients (50%) and led to withdrawal of PER in three cases and dose reduction in three, with abatement of the problems. SIGNIFICANCE: This study provides evidence that for ULD patients, PER may show marked efficacy even in severe cases, particularly against myoclonus, but also against seizures. PER should thus be tried in ULD patients whose seizures are not satisfactorily controlled. Its use is limited because of psychological and behavioral side effects, with higher doses of approximately 6 mg/day or greater likely risk factors.

Keywords:

Perampanel,380917-97-5,Natural Products,AMPAR, buy Perampanel , Perampanel supplier , purchase Perampanel , Perampanel cost , Perampanel manufacturer , order Perampanel , high purity Perampanel

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: